comparemela.com

Latest Breaking News On - National pharmaceutical regulatory division - Page 8 : comparemela.com

3,000 to be invited to participate in vaccine trials

PETALING JAYA: Three thousand Malaysian adults will be invited to participate in the phase three clinical trials for a new vaccine manufactured by Chinese firm Shenzhen Kangtai Biological Products Co Ltd, says the Health Ministry. Health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study involving the inactivated vaccine was approved by the National Pharmaceutical Regulatory Division (NPRA) on May 28. The third phase of the clinical study of this vaccine would be conducted in eight research centres in Malaysia targeting the participation of 3,000 adults aged 18 and above and was expected to take 15 to 19 months, he said. “The Health Ministry would like to inform that there is an addition of one clinical study, involving the product SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL manufactured by Shenzhen Kangtai Biological Products Co Ltd from China.

Almost a million doses of Sinovac vaccine expected to be administered by end of April

Almost a million doses of Sinovac vaccine expected to be administered by end of April 01 Apr 2021 / 22:45 H. Pix for representational purpose only. KUALA LUMPUR: Almost one million doses of the Sinovac vaccine from China are expected to be administered by the end of April, says Pharmaniaga Berhad (Pharmaniaga) managing director Datuk Zulkarnain Md Eusope. He said this would be possible after the batch manufacturing process validation (PV) data and vaccine stability study data could be provided by mid-April to complete the registration application before it is approved by the National Pharmaceutical Regulatory Division (NPRA). The first dose of the vaccine was given on March 18.

Pharmaniaga: Almost a million doses of Sinovac vaccine expected to be administered by end of April | Malaysia

Thursday, 01 Apr 2021 09:45 PM MYT Pharmaniaga MD Datuk Zulkarnain Md Eusope said the target would also help meet the government’s expectation that Pharmaniaga would be able to produce two million doses of the Sinovac vaccine every month to ensure a stable supply in Malaysia. China Daily pic via Reuters Subscribe to our Telegram channel for the latest updates on news you need to know. KUALA LUMPUR, April 1 Almost one million doses of the Sinovac vaccine from China are expected to be administered by the end of April, says Pharmaniaga Berhad (Pharmaniaga) managing director Datuk Zulkarnain Md Eusope. He said this would be possible after the batch manufacturing process validation (PV) data and vaccine stability study data could be provided by mid-April to complete the registration application before it is approved by the National Pharmaceutical Regulatory Division (NPRA).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.